OXiGENE Announces $7.5 Million Financing
March 11, 2010 09:40 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports Fourth Quarter and Year-End 2009 Results
February 25, 2010 16:16 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Fourth Quarter and Fiscal 2009 Earnings Conference Call and Webcast
February 19, 2010 16:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
February 11, 2010 10:43 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE,
Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage,
biopharmaceutical company developing novel therapeutics to treat...
OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen
February 04, 2010 09:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 4, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference
December 07, 2009 09:51 ET
|
Oxigene, Inc.
Greater Antileukemic Activity Shown with OXi4503 Alone or Combined with
Bevacizumab than Bevacizumab Alone
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN)...
OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference
November 17, 2009 12:30 ET
|
Oxigene, Inc.
Combination of ZYBRESTAT With Bevacizumab Appears Well-Tolerated; Fewer Patient
Deaths in Treatment Arm
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN)...
OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings
November 12, 2009 16:01 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences
November 10, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports Third Quarter 2009 Financial Results
November 09, 2009 02:00 ET
|
Oxigene, Inc.
Upcoming Milestones Include Presentation of Key Randomized Data in Phase 2
Study of ZYBRESTAT in Patients With Non-small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2009 (GLOBE NEWSWIRE)...